secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CIK:        0001870404
Form:       8-K
Filed at:   2024-11-18T23:59:59+00:00
Accession:  0001213900-24-099354
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA clears IND for CER-1236 Phase 1 trial in AML; start expected Q1 2025
------------------------------------------------------------------------

- FDA cleared CERo's IND for Phase 1 trial of CER-1236 in acute myelogenous leukemia (AML).
- Interim CEO Chris Ehrlich said first in-human trial expected to begin Q1 2025.
- CER-1236 uses the Chimeric Engulfment Receptor T cell (CER-T) platform targeting hematologic malignancies.
- CERo believes CER-T cells may offer broader application than CAR-T, including solid tumors.
- Company to deploy resources expeditiously; shares recent program update as key milestone.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1870404/000121390024099354/0001213900-24-099354-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1870404/000121390024099354/ea0221421-8k_cerothera.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-099354

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer